跳至主要内容
临床试验/NCT05123248
NCT05123248已完成不适用

Integrating the Use of Calibration-Free Continuous Monitoring for Pregnancy Glucose Profiling: I-Profile Study

KK Women's and Children's Hospital2 个研究点 分布在 1 个国家目标入组 240 人开始时间: 2018年10月16日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
240
试验地点
2
主要终点
Gestational Diabetes Mellitus (GDM)

研究概览

简要总结

This study aims to test the following hypotheses in a longitudinal, observational study in pregnant women who will be randomized to received either a Blinded or Unblinded CGM sensor and followed-up 6-12 weeks after delivery:

  1. CF-CGM device is well tolerable and accurate for glucose level monitoring in women with a normal pregnancy.
  2. CF-CGM device is well tolerable and acceptable in women with GDM who are required intensive glucose monitoring on a daily basis during pregnancy and even after delivery.
  3. There are trimester-specific glucose profiles observed in the whole pregnancy.
  4. Pregnancies complicated with GDM would show a specific glucose profile that is different from non-GDM pregnancies (e.g. greater daily fluctuations, more episodes and longer duration of glucose spikes after meal).
  5. There is a good correlation between one-day glucose profile and OGTT test at 24-31 weeks gestation GDM screening.
  6. Pre-GDM screening glucose profiles is predictive of GDM diagnosis at 24-31 weeks gestation.

详细描述

GDM affects 5-10% of pregnant women in Europe, while the prevalence in Asian populations is significantly higher at approximately 15-20%. However, the GDM screening approaches, timing and targeted population still varies greatly in clinical practice all over the world, which makes the prevalence of GDM difficult to compare universally. Since the early days of the 21st century, the continuous glucose monitoring system (CGM) has been used for constant evaluation of glucose levels by measuring interstitial glucose concentrations. It can potentially improve diabetes care if used carefully with proper understanding of the characteristics of this system.

This is longitudinal, observational and hospital-based study. A total of 500 pregnant women will be recruited with consent form completion after meeting our inclusion criteria. The recruited women will then be randomly assigned to a Blinded and Unblinded CGM device.

All pregnant women aged 21 and above who plan to be followed up throughout pregnancy and intend to deliver at KKH and currently attending KKH for antenatal consultation during their early trimester will be approached by study research personnel, and will be followed up from then onwards. If they agree to take part in the study, consent will be signed at the first trimester clinic visit.

All recruited subjects will be randomized to put on a Blinded or Unblinded CGM device for 14 days from the first trimester (9-13 weeks), 18-23 weeks, 24-31 weeks, and 32-33 weeks. If a pregnant subject is diagnosed with GDM using International association of diabetes and pregnancy study groups (IADPSG) guidelines at KKH at 24-31 weeks gestation, she will be required to wear the sensor continuously until 38 weeks gestation, and will be followed up for another 14 days at the 6-12 weeks postnatal period.

Data will be collected through questionnaires and clinical measurements. The questionnaires include socio-economic factors, medical histories, lifestyle factors, health status, and home environment. Bio-physical measurements will be obtained from anthropometric measurements of participants, human biological materials such as blood, are collected from the participants at their follow-up time points with the I-PROFILE study upon their consent.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
21 Years 至 65 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Participants who are Singapore citizens or Singapore Permanent Residents, and plan to be followed up throughout pregnancy and intend to deliver at KKH;
  • Aged 21 and above;
  • Singleton pregnancy

排除标准

  • Have serious skin conditions (e.g. eczema) that precludes wearing the sensor for 14 days;
  • Patients who have any other chronic disease such as chronic kidney disease.
  • Unable to read or speak English

结局指标

主要结局

Gestational Diabetes Mellitus (GDM)

时间窗: 24-31 weeks gestation

Clinical outcomes of Gestational Diabetes Mellitus (GDM) development determined by oral glucose tolerance test

次要结局

  • CGM summary metrics derived from extracted CGM glucose data(First trimester: 9-13 weeks, Second trimester: 18-23 weeks, 24-31 weeks, 32-33 weeks)
  • Plasma glucose measures from OGTT(24-31 weeks gestation)

研究者

发起方
KK Women's and Children's Hospital
申办方类型
Other Gov
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Integrating the Use of Calibration-Free Continuous... | 临床试验